Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jaclyn Neveu

Physician Assistant, Medical Norwich, CT Physician Assistant

NPI 1669031563 CMS profile 11025927

164 Otrobando Ave, Norwich, CT 06360

Open in the dashboard

General payments

$7,829

109 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jaclyn Neveu of Norwich, CT is reported in the CMS Open Payments database as having received $7,829 across 109 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,161 19
2024 General $2,320 37
2023 General $401 13
2022 General $3,933 39
2021 General $14 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jaclyn Neveu
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Jaclyn Neveu were reported at $1,161. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Jaclyn Neveu Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $14 $156 $41–$563 $132
2022 $3,933 $185 $55–$649 $149
2023 $401 $199 $58–$717 $160
2024 $2,320 $206 $62–$740 $164
2025 $1,161 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $4,180 35 payments
  2. Impulse Dynamics (USA) Inc. $1,369 19 payments
  3. Boston Scientific Corporation $1,306 26 payments
  4. Abbott Laboratories $229 9 payments
  5. E.R. Squibb & Sons, L.L.C. $218 6 payments
  6. Atricure, Inc. $156 2 payments
  7. AstraZeneca Pharmaceuticals LP $150 2 payments
  8. Pfizer Inc. $135 6 payments
  9. Baxter Healthcare $28 1 payment
  10. Novo Nordisk Inc $24 1 payment
  11. Other $33 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Travel and Lodging $4,370 17 payments
  2. Food and Beverage $3,409 88 payments
  3. Education $50 4 payments
Products named General payments · program years 2021–2025
  1. OPTIMIZER Cardiovascular Device $1,328 12 payments
  2. OPTIMIZER Cardiovascular Device $1,328 12 payments
  3. SelectSecure $1,289 2 payments
  4. WATCHMAN FLX $1,128 17 payments
  5. CAMZYOS $193 4 payments
  6. Micra $163 1 payment
  7. PULSESELECT $160 1 payment
  8. WAINUA $150 2 payments
  9. ELIQUIS $135 6 payments
  10. LINQ II $134 3 payments
  11. Other $898 46 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

1,220

Median for Physician Assistant: 241

Drug cost

$437,959

Median for Physician Assistant: $4,110

Branded share of claims

29.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 256 $328,218
Xarelto Rivaroxaban Brand 46 $59,920
Dofetilide Generic 80 $23,209
Mexiletine Hcl Generic 120 $14,447
Metoprolol Succinate Generic 305 $4,976
Flecainide Acetate Generic 42 $2,477
Amiodarone Hcl Generic 99 $1,833
Sotalol Sotalol Hcl Brand 26 $770
Metoprolol Tartrate Generic 76 $580
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 23 $537

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$35,265

Medicare's payments for the services billed

Medicare patients

191

Average age 76

Services billed

632

70 women, 121 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 75%
Heart failure 58%
Ischemic heart disease 52%
Arthritis 48%
Diabetes 38%
Chronic kidney disease 36%
COPD 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $175
$175 — —
WAINUA
  • AstraZeneca Pharmaceuticals LP $123
$123 — —
ELIQUIS
  • PFIZER INC. $46
  • E.R. Squibb & Sons, L.L.C. $9
$55 256 —
PAXLOVID
  • PFIZER INC. $46
$46 — —
RYBELSUS
  • Novo Nordisk Inc $12
$12 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

109 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record